Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoural Tigilanol Tiglate in Advanced Melanoma
NCT05234437Phase 2Terminated
- Sponsor
- QBiotics Group Limited
- Start
- Mar 2022
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tigilanol tiglate in melanoma, sponsored by QBiotics Group Limited. Started Mar 2022; status: terminated.
02
Drugs
tigilanol tiglate
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05234437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234437.